Want to see INDP full AI Analyst Report?
Top Page
Indaptus Therapeutics
(NASDAQ:INDP)
Select Model
Select Model
Rating:51Neutral
Price Target:
$3.00
▲(172.73% Upside)
Action:Reiterated
Date:10/21/26
The score is held down primarily by weak financial performance (pre-revenue, ongoing losses and cash burn) and limited valuation support (negative P/E, no dividend). Offsetting factors include improving technical trend/momentum and liquidity bolstered by recent private placements, though dilution and strategic-reset risk temper the benefit.
Positive Factors
Debt-free balance sheet
Zero debt and a 0 debt-to-equity ratio reduce refinancing and interest-rate exposure. This gives the company a cleaner capital structure and preserves flexibility to direct future funding toward research or strategic initiatives, although it does not offset operating losses.
Negative Factors
Pre-revenue business model
Indaptus has not yet demonstrated commercial revenue, leaving its financial profile dependent on funding and future development outcomes. Without product sales, the company lacks an operating revenue base to absorb costs or provide evidence of sustainable market demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero debt and a 0 debt-to-equity ratio reduce refinancing and interest-rate exposure. This gives the company a cleaner capital structure and preserves flexibility to direct future funding toward research or strategic initiatives, although it does not offset operating losses.
Read all positive factors
Indaptus Therapeutics (INDP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$485.32M
Dividend YieldN/A
Average Volume (3M)652.90K
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue GrowthN/A
EPS Growth81.43%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.97
Shares Outstanding153,581,300
10 Day Avg. Volume419,353
30 Day Avg. Volume652,900
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.89
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.80
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.34
Revenue Forecast (FY)N/A
Indaptus Therapeutics Business Overview & Revenue Model
Company Description
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compou...
Indaptus Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -15.45M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
| Net Income | -15.42M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
Balance Sheet | ||||||
| Total Assets | 11.99M | 9.31M | 7.34M | 14.92M | 28.06M | 40.58M |
| Cash, Cash Equivalents and Short-Term Investments | 11.55M | 8.51M | 5.79M | 13.36M | 26.43M | 39.13M |
| Total Debt | 0.00 | 0.00 | 84.16K | 175.05K | 80.49K | 169.33K |
| Total Liabilities | 615.43K | 6.16M | 3.39M | 2.85M | 3.43M | 4.68M |
| Stockholders Equity | 11.37M | 3.15M | 3.94M | 12.08M | 24.63M | 35.90M |
Cash Flow | ||||||
| Free Cash Flow | -15.18M | -14.82M | -12.32M | -13.41M | -13.25M | -11.29M |
| Operating Cash Flow | -15.18M | -14.82M | -12.32M | -13.41M | -13.08M | -11.29M |
| Investing Cash Flow | -4.00M | 0.00 | 0.00 | 17.14M | -16.43M | 447.75K |
| Financing Cash Flow | 20.58M | 17.54M | 4.75M | 0.00 | 0.00 | 48.34M |
Indaptus Therapeutics Technical Analysis
Positive
1.10
Price Trends
2.33
Positive
2.45
Positive
2.29
Positive
Market Momentum
0.12
Negative
57.49
Neutral
85.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDP, the sentiment is Positive. The current price of 1.1 is below the 20-day moving average (MA) of 2.63, below the 50-day MA of 2.33, and below the 200-day MA of 2.29, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 57.49 is Neutral, neither overbought nor oversold. The STOCH value of 85.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INDP.
Indaptus Therapeutics Risk Analysis
Indaptus Therapeutics disclosed 65 risk factors in its most recent earnings report. Indaptus Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Indaptus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $485.32M | -0.45 | -302.75% | ― | ― | 81.43% | |
47 Neutral | $183.84M | -2.17 | 44.63% | ― | 3.03% | 57.71% | |
43 Neutral | $183.27M | -2.38 | -91.60% | ― | 3472.96% | 67.74% | |
42 Neutral | $128.21M | -1.14 | -39.64% | ― | ― | -6.70% | |
40 Underperform | $13.77M | -0.22 | -108.72% | ― | 2.15% | 17.34% | |
38 Underperform | $76.17M | -1.61 | -94.14% | ― | -0.11% | -13.99% |
* Healthcare Sector Average
INDP
Indaptus Therapeutics
3.34
-0.21
-5.92%
CLLS
Cellectis SA
0.97
-2.66
-73.39%
DTIL
Precision BioSciences
6.41
-0.77
-10.72%
ADCT
ADC Therapeutics
1.51
-2.78
-64.80%
NKTX
Nkarta
1.83
-0.52
-22.13%
TCRX
TScan Therapeutics
0.19
-2.09
-91.71%
Indaptus Therapeutics Corporate Events
Private Placements and Financing
Indaptus completes private placement to bolster capital base
Positive
Oct 20, 2026
On October 16, 2026, Indaptus Therapeutics completed a private placement financing transaction, receiving the full purchase price from all participating investors under an amended purchase agreement. In connection with this closing, the company is...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Indaptus Therapeutics Extends Timeline for Private Placement Financing
Positive
Sep 30, 2026
On September 8, 2026, Indaptus Therapeutics, Inc. entered into a Stock Purchase Agreement with certain purchasers for a private placement of common stock expected to generate approximately $24.0 million in gross proceeds, as previously disclosed i...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Indaptus Therapeutics Announces Private Equity Financing Deal
Positive
Sep 10, 2026
On September 8, 2026, Indaptus Therapeutics entered into a Stock Purchase Agreement to sell 20,338,974 shares of common stock in a private placement, raising approximately $24.0 million in gross proceeds. The company plans to use the net funds for...
Executive/Board Changes
Indaptus Therapeutics Announces Routine Board Member Resignation
Neutral
Sep 4, 2026
On September 2, 2026, Indaptus Therapeutics, Inc. announced that Board member Tim Ruan resigned from the company’s Board of Directors, effective immediately. The company stated that Ruan’s departure did not arise from any disagreement ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Indaptus Updates ATM Agreement to Expand Capital Flexibility
Neutral
Sep 1, 2026
On August 28, 2026, Indaptus Therapeutics, Inc. amended and restated its at-the-market equity offering agreement with H.C. Wainwright Co., allowing the company to sell up to $100 million of common stock from time to time through the investment ba...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingShareholder Meetings
Indaptus Therapeutics Reports Q2 Results Amid Strategic Pivot
Negative
Aug 13, 2026
Indaptus Therapeutics held its 2026 annual meeting of stockholders on August 10, 2026, where shareholders elected three Class II directors for terms running to 2029, ratified Haskell White LLP as independent auditor for 2026 and approved a new eq...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.